Medicaid Clinical Prior Authorization Updates Scheduled

Texas Health and Human Services Commission sent this bulletin at 07/08/2020 08:09 AM CDT / Este e-mail ha sido enviado por Texas Health and Human Services Commission el 07/08/2020 08:09 AM CDT

Medicaid Clinical Prior Authorization Updates Scheduled

The Texas Vendor Drug Program routinely updates existing clinical prior authorization criteria to reflect recent FDA-approved indications or safety information from the product package insert. VDP will make the following changes in the months ahead:

Revising the Dupixent (dupilumab) clinical prior authorization on Aug. 24, 2020
Revising the Eucrisa (crisaborole) criteria within the Topical Immunomodulators clinical prior authorization on Aug. 24, 2020
Revising the Austedo (deutetrabenazine) criteria within the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors clinical prior authorization on Sept. 21, 2020

These prior authorizations are optional for Medicaid managed care. Specific criteria changes are available online on the VDP website.

You have subscribed to get updates about Texas Health and Human Services (HHS). For more information about HHS, please visit our website.

Stay Connected
					(en español)

Subscriber Services
Manage Preferences | Unsubscribe | Help